Familial Chylomicronemia Syndrome (FCS)- Epidemiology Forecast to 2030

Overview
‘Familial Chylomicronemia Syndrome (FCS)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted FCS epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Familial Chylomicronemia Syndrome (FCS) Understanding
Familial Chylomicronemia Syndrome (FCS) is a rare genetic lipid disorder that is associated with the buildup of chylomicrons (a large lipoprotein particle that transports dietary fat and cholesterol in the body). It is also known as lipoprotein lipase deficiency (LPLD), Type 1 hyperlipoproteinemia, endogenous hypertriglyceridemia, familial fat-induced hypertriglyceridemia, familial hyperchylomicronemia, and familial LPL deficiency, hyperlipidemia Type I (fredrickson), hyperlipoproteinemia Type IA, lipase D deficiency, and Burger-Grutz syndrome
The normal triglyceride levels are <150 mg/dL (or 1.7 mmol/L), but as the patients with FSC are incapable of breaking down chylomicrons (CM) that are rich in triglycerides, the levels can be as high as 10–20 times the normal threshold. FCS patients are at risk of severe recurrent abdominal pain and potentially fatal pancreatitis, long-term complications from pancreatic damage, and symptoms that can interfere with daily living. The leading cause behind the increase in the CM is the reduction or absence of LPL, which is an enzyme that helps to break down CM in the body. The patients with FCS encounter several severe symptoms before it is diagnosed.
The sign and symptoms that patients may experience include xanthomas (fatty deposits in the skin, usually on buttocks, knees, and arms), hepatosplenomegaly (swelling of liver and spleen), lipemia retinalis (milky appearance of retinal veins and arteries), and neurological symptoms such as depression and memory loss.
The clinical progression of FCS is unclear, in some cases, the patient may develop symptoms, including abdominal pain, quiet early in life, but may not be diagnosed until they are in their teens or 20s when the pancreatitis attacks become more frequent. Due to disease rarity and lack of understanding, FCS is often misdiagnosed or undiagnosed; however, the most number of patients have their diagnosis confirmed by a genetic test. Recently FCS score is developed to combat with misdiagnosis of FCS with multifactorial chylomicronemia syndrome (MCS).
Epidemiology Perspective by Report
The FCS epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The FCS epidemiology data are studied through FCS possible division to give a better understanding of the Disease scenario in the 7MM.
The disease epidemiology covered in the report provides historical as well as forecasted Familial Chylomicronemia Syndrome epidemiology [segmented as Total Prevalence of FCS, Total Diagnosed Prevalence of FCS, Age-specific Diagnosed Prevalence of FCS, Severity- Specific Diagnosed Prevalence of FCS, and Treated Patient Pool of FCS] scenario of Familial Chylomicronemia Syndrome in the 7MM covering the United States, EU5 countries (Germany, France, Italy , Spain, and the United Kingdom), and Japan from 2017 to 2030.
Familial Chylomicronemia Syndrome Detailed Epidemiology Segmentation
The total prevalent cases of FCS in the 7MM were found to be 5,801 in 2017 which is expected grow during the study period, i.e., 2017–2030.
Estimates show the highest prevalent population of FCS is in the United States followed by Japan, Germany, France, and the United Kingdom in 2017.
The total diagnosed prevalent population of FCS in the 7MM was assessed to be 2,900 in 2017 which is expected to increase during the study period.
FCS has been observed across all ages and this makes age as one of the major factors for this condition. During the understanding of this indication and analyses of the various research paper, we have observed that FCS cases are most commonly diagnosed in younger population (infants and younger adults). In 2017, higher number of cases estimated for the age group 0–10 years. Estimated number of cases in other age-groups were comparatively low.
About 70% of the total diagnosed prevalent cases were interfered significantly with their self-worth, emotional well-being, sleep, and mental functioning.
Scope of the Report
• The FCS report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
• The FCS Report and Model provide an overview of the risk factors and global trends of FCS in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of FCS in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of FCS.
• The report provides the segmentation of the FCS epidemiology by Diagnosed Prevalent Cases of FCS in the 7MM.
• The report provides the segmentation of the FCS epidemiology by Age-specific Diagnosed Prevalent Cases of FCS in the 7MM.
• The report provides the segmentation of the FCS epidemiology by Severity- Specific Diagnosed Prevalent of FCS in the 7MM.
• The report provides the segmentation of the FCS epidemiology by Treated Patient Pool of FCS in the 7MM.
Report Highlights
• 11-Year Forecast of Familial Chylomicronemia Syndrome epidemiology
• 7MM Coverage
• Total Prevalent Cases of Familial Chylomicronemia Syndrome
• Prevalent Cases according to segmentation: Age-specific, Severity-specific
• Treated cases of Familial Chylomicronemia Syndrome
KOL-Views
We interview, KOL’s and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over FCS scenario of the indications.
Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Familial Chylomicronemia Syndrome?
• What are the key findings pertaining to the Familial Chylomicronemia Syndrome epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of Familial Chylomicronemia Syndrome across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of Familial Chylomicronemia Syndrome?
• Percentage of Familial Chylomicronemia Syndrome patients who are significantly affected in terms of their self-worth, emotional well-being, sleep, and mental functioning?
Reasons to buy
The Familial Chylomicronemia Syndrome Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Familial Chylomicronemia Syndrome market
• Quantify patient populations in the global Familial Chylomicronemia Syndrome market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Familial Chylomicronemia Syndrome therapeutics in each of the markets covered
• Understand the magnitude of Familial Chylomicronemia Syndrome population by its severity
• The Familial Chylomicronemia Syndrome epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Familial Chylomicronemia Syndrome Epidemiology Model developed by Report is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
Total Prevalent cases of FCS in the 7MM was assessed to be 5,801 in 2017, and are expected to increase during the study period. Among the European 5 countries, Germany had highest prevalent population of FCS, followed by France, United Kingdom and Italy. On the other hand, Spain had the lowest prevalent cases of FCS in 2017. Furthermore, Japan accounts for the 22% of the 7MM total prevalent patient population of FCS.